Savara (NASDAQ:SVRA) Stock Price Up 5.5% Following Analyst Upgrade

Shares of Savara Inc (NASDAQ:SVRA) were up 5.5% during mid-day trading on Friday after Guggenheim raised their price target on the stock from $8.00 to $10.00. Guggenheim currently has a buy rating on the stock. Savara traded as high as $4.08 and last traded at $4.02. Approximately 512,708 shares traded hands during trading, a decline of 55% from the average daily volume of 1,146,644 shares. The stock had previously closed at $3.81.

Other equities analysts have also recently issued reports about the company. Piper Sandler lifted their price objective on Savara from $7.00 to $16.00 and gave the stock an “overweight” rating in a report on Monday, March 4th. JMP Securities reaffirmed a “market outperform” rating and set a $8.00 price target on shares of Savara in a research note on Monday, May 6th. Evercore ISI lowered their price objective on shares of Savara from $10.00 to $7.00 and set an “outperform” rating on the stock in a research note on Thursday, May 16th. Oppenheimer lifted their target price on shares of Savara from $11.00 to $15.00 and gave the stock an “outperform” rating in a research report on Wednesday. Finally, HC Wainwright increased their price target on shares of Savara from $6.00 to $10.00 and gave the company a “buy” rating in a research report on Thursday. Six investment analysts have rated the stock with a buy rating, Based on data from MarketBeat.com, the company currently has a consensus rating of “Buy” and an average price target of $11.00.

Institutional Inflows and Outflows

Several institutional investors have recently added to or reduced their stakes in the company. Opaleye Management Inc. purchased a new stake in Savara in the 1st quarter worth approximately $4,258,000. California State Teachers Retirement System increased its stake in Savara by 411.0% during the 1st quarter. California State Teachers Retirement System now owns 75,986 shares of the company’s stock worth $378,000 after buying an additional 61,117 shares during the period. AWM Investment Company Inc. acquired a new position in shares of Savara in the first quarter worth about $498,000. Janus Henderson Group PLC boosted its holdings in Savara by 41.1% in the first quarter. Janus Henderson Group PLC now owns 2,563,620 shares of the company’s stock valued at $12,754,000 after purchasing an additional 746,407 shares during the last quarter. Finally, Bain Capital Life Sciences Investors LLC grew its stake in Savara by 2.3% during the 1st quarter. Bain Capital Life Sciences Investors LLC now owns 14,565,457 shares of the company’s stock valued at $72,536,000 after purchasing an additional 332,706 shares in the last quarter. Institutional investors and hedge funds own 87.93% of the company’s stock.

Savara Stock Up 5.8 %

The firm has a fifty day simple moving average of $4.30 and a 200-day simple moving average of $4.63. The company has a market capitalization of $556.91 million, a PE ratio of -10.89 and a beta of 0.70. The company has a debt-to-equity ratio of 0.22, a quick ratio of 14.90 and a current ratio of 14.90.

Savara (NASDAQ:SVRA) last issued its earnings results on Thursday, May 9th. The company reported ($0.11) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.10) by ($0.01). Equities research analysts anticipate that Savara Inc will post -0.41 EPS for the current fiscal year.

Savara Company Profile

Savara Inc, formerly Mast Therapeutics, Inc, is a clinical-stage pharmaceutical company. The Company is focused on the development and commercialization of novel therapies for the treatment of patients with rare respiratory diseases. Its pipeline includes AeroVanc, Molgradex and AIR001. AeroVanc is an inhaled formulation of vancomycin, which the Company is developing for the treatment of persistent methicillin-resistant Staphylococcus aureus, lung infection in cystic fibrosis patients.